Clinical Trials for Tahoe Forest Cancer Center

Select a primary disease below to jump to that section
Bladder/Urothelial Cancer Brain Cancer/Metastases Breast Cancer Colorectal Cancer
Kidney Cancer Lung Cancer Miscellaneous Multiple Myeloma
Pancreatic Cancer Prostate Cancer    

Bladder/Urothelial Cancer Back To Top
 
A031501
(Age 18 or above)
Clinical research coordinator: Rachel Kitchen - Ph: (530) 582-6450
Phase III Randomized Adjuvant Study of MK-3475 (Pembrolizumab) in Muscle Invasive and Locally Advanced Urothelial Carcinoma (AMBASSADOR) verses Observation
 
Brain Cancer/Metastases Back To Top
 
NRG-CC003
(Age 18 or above) (temporary closure)
Clinical research coordinator: Rachel Kitchen - Ph: (530) 582-6450
A Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer
 
RTOG 0631
(Age 18 or above)
Clinical research coordinator: Rachel Kitchen - Ph: (530) 582-6450
Phase II/III Study of Image-guided Radiosurgery/SBRT for Localized Spine Metastasis
 
Breast Cancer Back To Top
 
A011202
(Age 18 or above)
Clinical research coordinator: Rachel Kitchen - Ph: (530) 582-6450
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
 
A011401
(Age 18 or above)
Clinical research coordinator: Rachel Kitchen - Ph: (530) 582-6450
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
 
A011502
(Age varies)
Clinical research coordinator: Rachel Kitchen - Ph: (530) 582-6450
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Her2 Negative Breast Cancer: The ABC Trial
 
NRG-BR002
(Age 18 or above)
Clinical research coordinator: Rachel Kitchen - Ph: (530) 582-6450
A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer
 
RTOG 1304 - NSABP B-51
(Age 18 or above)
Clinical research coordinator: Rachel Kitchen - Ph: (530) 582-6450
A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
 
S1207
(Age 18 or above)
Clinical research coordinator: Rachel Kitchen - Ph: (530) 582-6450
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer
 
S1416
(Age 18 or above)
Clinical research coordinator: Rachel Kitchen - Ph: (530) 582-6450
Phase II Randomized Placebo-Controlled Trial of Cisplatin with or without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer
 
S1418-BR006
(Age 18 or above)
Clinical research coordinator: Rachel Kitchen - Ph: (530) 582-6450
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with >/= 1 CM 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant Chemotherapy
 
UCDCC#242
(Age varies) (temporary closure)
Clinical research coordinator: Rachel Kitchen - Ph: (530) 582-6450
Early Stage Breast Cancer and Aromatase Inhibitor Pathway Protocol
 
Colorectal Cancer Back To Top
 
UCDCC#241
(Age 18 or above)
Clinical research coordinator: Rachel Kitchen - Ph: (530) 582-6450
Gastrointestinal Cancer Research Program-001: Advanced Colorectal Cancer Pathway Protocol
 
Colorectal Cancer: Rectal
 
NRG-GI002
(Age 18 or above) (temporary closure)
Clinical research coordinator: Rachel Kitchen - Ph: (530) 582-6450
A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer
 
Kidney Cancer Back To Top
 
EA8143
(Age 18 or above)
Clinical research coordinator: Rachel Kitchen - Ph: (530) 582-6450
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
 
S1500
(Age 18 or above)
Clinical research coordinator: Rachel Kitchen - Ph: (530) 582-6450
A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)
 
Lung Cancer Back To Top
 
E4512
Clinical research coordinator: Rachel Kitchen - Ph: (530) 582-6450
A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
 
S1400
(Age 18 or above) (temporary closure) (partial closure)
Clinical research coordinator: Rachel Kitchen - Ph: (530) 582-6450
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer
 
Lung Cancer: Non Small Cell
 
A081105
(Age 18 or above)
Clinical research coordinator: Rachel Kitchen - Ph: (530) 582-6450
Randomized Study of Erlotinib vs Observation in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC) ALCHEMIST SUB-STUDY
 
A151216
(Age 18 or above)
Clinical research coordinator: Rachel Kitchen - Ph: (530) 582-6450
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
 
EA5142
(Age 18 or above)
Clinical research coordinator: Rachel Kitchen - Ph: (530) 582-6450
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) ? A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
 
NRG-LU002
(Age 18 or above)
Clinical research coordinator: Rachel Kitchen - Ph: (530) 582-6450
Maintenance Systemic Therapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Systemic Therapy For Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
 
Lung Cancer: Small Cell
 
CTSU C30610
(Age 18 or above)
Clinical research coordinator: Rachel Kitchen - Ph: (530) 582-6450
Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin or Carboplatin and Etoposide
 
Miscellaneous Back To Top
 
S1609
(Age 18 or above)
Clinical research coordinator: Rachel Kitchen - Ph: (530) 582-6450
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
 
Multiple Myeloma Back To Top
 
E1A11
(Age 18 or above)
Clinical research coordinator: Rachel Kitchen - Ph: (530) 582-6450
Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
 
Pancreatic Cancer Back To Top
 
A021501
(Age 18 or above) (temporary closure)
Clinical research coordinator: Rachel Kitchen - Ph: (530) 582-6450
Preoperative Extended Chemotherapy vs. Chemotherapy Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas
 
S1609
(Age 18 or above)
Clinical research coordinator: Rachel Kitchen - Ph: (530) 582-6450
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
 
Prostate Cancer Back To Top
 
CCRO025
(Age 18 or above)
Clinical research coordinator: Rachel Kitchen - Ph: (530) 582-6450
Whole-Pelvic Radiotherapy with a Stereotactic Body Radiotherapy Boost and Long-Term Androgen Deprivation for Unfavorable-Intermediate and High Risk Localized Adenocarcinoma of the Prostate: A Prospective Feasibility Study
 
NRG-GU002
(Age 18 or above)
Clinical research coordinator: Rachel Kitchen - Ph: (530) 582-6450
Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel
 
NRG-GU005
(Age 18 or above)
Clinical research coordinator: Rachel Kitchen - Ph: (530) 582-6450
Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer
 
RTOG 0924
(Age 18 or above)
Clinical research coordinator: Rachel Kitchen - Ph: (530) 582-6450
Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
 

For information about adult cancer clinical trials at Gene Upshaw Memorial Tahoe Forest Cancer Center, please call (530) 582-6438.
For information about clinical trials at other leading cancer centers around the country, please call 1 (800) 4-CANCER.